History of Nippon Shinyaku -As a Pharmaceutical Company from Kyoto-

Nippon Shinyaku has continuously created new, distinctive medicines needed in every era as a research and developmentoriented new drug manufacturer to help people lead healthier, happier lives. The foundation of the Company is its venture spirit, which is reflected in the words of the founder, "Making Japanese medicines with Japanese hands." Nippon Shinyaku aims to realize a society where people around the world can live healthily, and will provide valuable products and services.



1919 Founding

- 1940 Domestic production of Santonin, a vermicide for roundworms
- 1957 Relocation of headquarters to current location (Minami-ku, Kvoto)
- **1961** Start of Functional Foods business
- 1962 Completion of a new research laboratory (now Building No. 3 of Discovery Research Laboratories) in the headquarters area
- **1964** Completion of Odawara plant (now Odawara Central Factory)
- 1967 Completion of new premises at the Tokyo Business Office

Founding period-1969

In 1940, Nippon Shinyaku succeeded in manufacturing Santonin in Japan, a vermicide for roundworms, which contributed greatly to the reduction of Japan's roundworm infection rate and to the growth of Nippon Shinyaku's business performance. In the 1960s, Nippon Shinyaku diversified its prescription medicines-related activities by creating new drugs through the expansion of its R&D system, including the completion of a new laboratory for discovering new drugs, and by introducing products through alliances with overseas companies. It also started its Functional Food Business at this time. The Company built its business foundation by completing construction of the Odawara Plant and building a network of sales bases.

1967

products

FY1992 ¥50.534 billion Surpassed ¥50 billion in sales



- 1970 Completion of a food technology research institute (current Food Development Laboratory)
- 1971 Opening of East Logistics Center
- 1982 Completion of the Main Central Research Lab (now Building No. 1 of Discovery Research Laboratories) in the Head Office area
- 1991 Opening of Tokyo Branch Office
- 1991 Opening of Düsseldorf Office
- 1994 Completion of Building No. 2 of the West Discovery Research Laboratories (now Building No. 2 of Discovery Research Laboratories) at the Head Office
- 1997 Opening of New York Office (transformed into the local subsidiary NS Pharma Inc. in 1999 and then moved to New Jersey in 2002)

1970-1999

Nippon Shinyaku strengthened its R&D structure by establishing the Main Central Research Lab (now Building No. 1 of Discovery Research Laboratories) and other facilities that comply with GLP standards that ensure the safety and appropriateness of non-clinical studies. In the 1990s, the Company opened offices in Germany and the U.S. and promoted globalization through business expansion in Japan, the U.S., and Europe. It launched unique new products in the fields of gastroenterology, cardiology, urology, and otorhinolaryngology, and concentrated business resources into the cultivation of mainstay drugs. In the Functional Food Business, the Company began providing health food ingredients.

2000-2013

FY2013

¥76.517 billion

Surpassed ¥75 billion in sales

Reinforcement of business foundation to respond to drastic changes in conditions

2000 Establishment of Business Philosophy and Management Policy Start of the 1st Medium-Term Management Plan

- 2002 Establishment of Code of Conduct for Nippon Shinyaku Group
- 2005 Functional Food Division renamed to Functional Food Company
- 2007 Establishment of world's longest RNA synthesis technology
- 2011 Opening of the Beijing Representative Office
- 2012 Relocation of Düsseldorf Office to UK and opening of London Office

2000-2013

In addition to clearly stating its Business Philosophy and Management Policy, Nippon Shinyaku formulated a Medium-Term Management Plan to clarify its corporate vision. It invested business resources in focal areas such as urology and hematology, and invested resources in research on nucleic acid drugs at the Discovery Research Laboratories in Tsukuba. By proactively searching for unmet medical needs, the Company has continuously launched products in areas not often handled by major companies, and some of these products have grown to become business drivers.

2014

Drug discovery and R&D that continuously pursues patient centricity

One of the Company's

representative long-selling

For benign prostatic



Roundworm vermicide wonder drug Santonin









First in Japan to obtain

indication for frequent

For pollakiuria Bladderon

1989 In-house discovered product with unique mechanism of action

For gastric ulcers Gaslon N



indication for MDS



benign prostatic hypertrophy Zalutia

First-in-class drug with new

For urinary disorder caused by

mechanism of action



2011

First in Japan to obtain







leukemia Cylocide injection

Long-standing key drug for

acute myeloid leukemia

1971



1979

urination

Strategy for the Future

Corporate Data

FY2017

¥101.448 billion Surpassed ¥100 billion in sales

FY2023 ¥148.255 billion

Highest record sales

2014–Present

Aiming to be a global healthcare company from Kyoto that is recognized worldwide

- 2016 Completion of clinical trial API manufacturing facility in Head Office area
- 2016 Start of Functional Food Company Supplements business
- 2021 Establishment of Chinese subsidiaries Beijing Nippon Shinyaku Co., Ltd. and Tianjin Nippon Shinyaku Co., Ltd.
- 2023 Establishment of Innovation Research Partnering, a drug discovery center in the U.S.
- 2024 Completion of Odawara Central Factory Nucleic Acid API **Purification Plant**

2014–Present

Under the theme of "pursuit of originality" set forth in the management strategy of the 5th and 6th Five-Year Medium-Term Management Plans, Nippon Shinyaku has worked to build a unique foundation by continuously launching new products. These include a small molecule compound and a nucleic acid drug discovered in-house that have achieved global expansion, and have led to the establishment and development of a new business model for the Company, such as starting its own marketing by the Group Company NS Pharma in the U.S. The 7th Five-Year Medium-Term Management Plan started in FY2024, and we will continue to promote our global business by prioritizing investments for future growth.

2016 In-house discovered product for a rare disease eagerly awaited worldwide For pulmonary arterial hypertension Uptravi



2020

First Made-in-Japan nucleic acid drug tackling an intractable disease



